Table 2

Gametocytaemia and mosquito level outcomes by treatment group and study.

Study & country
 Treatment
Parasitological
treatment
failure (%)
Mean
AUC
per day
% gametocyte
slide-positive
at transmission
experiment
N transmission
experiments
(patients)
%
mosquitoes
infected*
Mean
oocyst
density
1. Gambia Targett 2001 [22]
 CQ
 59.3
 67.4
 17.4
 21
 13.4
 3.1

SP
 12.9
 117.6
 37.8
 57
 5.5
 0.5

SP-AS1
 3.8
 3.4
 16.3
 22
 8.7
 0.5

SP-AS3
 0
 11.9
 25.4
 12
 18.8
 5.2

all
 23.9
 66.2
 27.6
 112
 9.0
 1.6
2. Gambia Targett 2001 [22]
 SP
 -†
 -†
 64.0
 20
 10.7
 1.5

SP-AS3

13.4
 20
 6.1
 0.3

all

23.3
 40
 8.4
 0.9
3. Gambia Drakeley 2004 [20]
 CQ
 73.5
 58.7
 49.5
 35
 13.1
 3.9

CQ-AS
 54.7
 36.4
 26.5
 32
 5.2
 0.4

all
 59.6
 42.0
 32.1
 67
 9.3
 2.1
4. Gambia Hallett 2006 [13]
 CQ
 73.5
 81.1
 54.2
 17
 5.5
 0.8

SP
 57.4
 216.2
 89.6
 30
 2.7
 0.2

CQ-SP
 19.4
 134.8
 61.3
 20
 4.6
 1.1

all
 46.0
 147.7
 64.8
 67
 4.0
 0.6
5. Gambia Sutherland 2005 [21]
 CQ-SP
 19.0
 44.6
 41.7
 22
 3.0
 0.1

AL
 15.0
 2.9
 5.8
 39
 0.1
 0.0

(Coartem)






all
 15.7
 9.9
 12.2
 61
 1.2
 0.1
6. Kenya Bousema 2006 [19]
 SP
 54.1
 19.2
 37.2
 71
 7.0
 -‡

SP-AQ
 13.4
 11.2
 31.6
 41
 4.7

SP-AS3
 17.9
 3.9
 9.6
 41
 2.6

AL
 4.1
 2.3
 6.8
 29
 4.1

(Coartem)






all
 25
 9.1
 21.7
 182
 5.0

Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-lumefantrine (Coartem), AQ = amodiaquine. AUC = area under the gametocyte density-time curve. For numbers of patients contributing to parasitology outcomes see Table 1.

* mean of percentages per patient

† follow up was only 14 days compared to 28 days in the other studies. Therefore study 2 was not included in analyses involving parasitological failure or the AUC

‡ Oocyst count data was not collected

Okell et al. Malaria Journal 2008 7:125   doi:10.1186/1475-2875-7-125